|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.04 USD | -0.78% |
|
+4.05% | +7.23% |
| Jan. 08 | Incyte Insider Sold Shares Worth $1,184,064, According to a Recent SEC Filing | MT |
| Jan. 08 | Goldman Sachs Adjusts Price Target on Incyte to $90 From $80, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCYTE CORPORATION | Biopharmaceuticals | -0.79% | +4.05% | +7.23% | +46.35% | +12.31% | 20.98B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- INCY Stock
- Charts Incyte Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
